Proactive Investors - Run By Investors For Investors

Callitas Health promotes Joshua Maurice to sales VP

Maurice’s promotion comes as the clinical-stage pharmaceutical development group advances its programs and partnerships
desk
Callitas Health is developing innovative remedies for weight management, female sexual health, cannabis delivery and other proprietary drugs

Callitas Health Inc (CSE:LILY) (OTCQB:MPHMF) said Tuesday that Joshua Maurice has been promoted to vice-president of sales and business development.

Maurice’s promotion comes as the clinical-stage pharmaceutical development group adds to its management and hires consultants to advance its programs and partnerships and build on this year’s progress.

READ: Callitas Health banks on CannaStrips and OTC products while swinging for the fence with blockbuster drugs

“We’ve seen important strides in the first months of 2019 across the women’s health, cannabinoid and infertility spaces and deepening partnerships with companies like NFI Consumer Healthcare and Lifestyles,” said James Thompson, CEO of Callitas, in a statement.

“Promoting Joshua to this new position allows us to utilize his talents to further capitalize on these advancements in the company,” he added.

Formed in early 2015, Callitas Health is developing innovative remedies for weight management, female sexual health, cannabis delivery technologies and other proprietary drugs.

Callitas shares slipped a cent to hit $0.10 in New York trade on Tuesday morning.

Contact Ellen Kelleher at [email protected]

View full LILY profile View Profile

Callitas Health Inc. Timeline

Related Articles

scientists in a lab
January 30 2019
The technology first drew the attention of ChemioCare CEO Pedro Lichtinger years ago while he oversaw Pfizer's global primary care business
Medical scanner
February 08 2019
The company’s digital platform and Artificial Intelligence (AI) software manages and helps interpret images from MRI (magnetic resonance imaging) and PRT (positron emission tomography) scanners
1550834286_shutterstock_651647128.jpg
February 22 2019
The company is developing drugs for blood disorders, metabolic diseases and curbing alcohol use
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use